Fate Therapeutics (FATE) Reports First Patient Treatwed with FT500 Successfully Completes Initial Safety Assessment
Tweet Send to a Friend
Fate Therapeutics, Inc. (NASDAQ: FATE) today announced that the first patient treated with FT500 successfully completed an initial safety assessment ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
